Many of his policies are unfavorable to the pharmaceutical industry and would involve dramatic changes.
“It’s up to the industry whether this is going to have to be a war or not,” Mr. Buttigieg told STAT.
Six policies included in Mr. Buttigieg’s plan, according to STAT:
- Similar to Nancy Pelosi’s bill, his plan would allow the HHS secretary to negotiate lower drug prices and penalize drugmakers who raise prices too high and refuse to negotiate.
- A drug company that refuses to negotiate with the HHS secretary would face a tax starting at 65 percent and going as high as 95 percent.
- The plan embraces a strategy called “march-in rights,” which would allow the government to approve generic drugs even when a brand-name drugmaker still has a valid patent.
- Generic and biosimilar drugs would be placed on the lowest insurance formulary tiers.
- Senior citizens’ out-of-pocket costs would be capped at $200 per month and $2,400 annually.
- Mr. Buttigieg has also mentioned cracking down on pay-for-delay patent settlements that allow brand-name drugmakers to pay generic drugmakers to delay bringing their drug to the market so the brand-name maker doesn’t have to face competition and lower its prices.
Read the full article here.
More articles on pharmacy:
How 4 hospital pharmacies are improving operations
The 10 most-valued pharma brands in the world
Merck to create spinoff women’s health company, focus on Keytruda
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.